CNTX
What one share of Context Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies (“bsAb”) for solid tumors. Our goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (“CLDN6”) x CD3 TCE, CT-95, a Mesothelin (“MSLN”) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (“Nectin-4”) x CD3 TCE.
Context Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.48 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.36 |
| Cash and investments | $0.47 |
| Book value | $0.42 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$3.96 | — | −$0.50 | — | — |
| 2021 | — | −$3.69 | $0.00 | −$3.11 | — | — |
| 2022 | — | −$0.93 | $0.00 | −$0.85 | — | $2.18 |
| 2023 | — | −$1.50 | $0.00 | −$1.32 | — | $0.74 |
| 2024 | — | −$0.46 | $0.00 | −$0.25 | — | $1.06 |
| 2025 | — | −$0.38 | $0.00 | −$0.28 | — | $0.66 |